top of page
Anti-IRTA1 (clone QM005)

Anti-IRTA1 (clone QM005)

IRTA1 (CD307d, FCRL4) – A Novel Diagnostic Marker for Marginal Zone Lymphoma (MZL)
IRTA1 (Immunoglobulin Superfamily Receptor Translocation-Associated 1), also known as Fc receptor-like 4 (FCRL4) or CD307d, is a protein belonging to the immunoglobulin-like receptor superfamily, which plays a role in modulating B-cell immune responses.
IRTA1 Expression in Normal and Neoplastic Tissues
✔ In normal lymphoid tissues, IRTA1 is expressed in:
      
  • Benign monocytoid B cells
    •   
  • Some marginal zone (MZ) cells
    •   
  • Intraepithelial B cells
    ✔ In lymphomas, IRTA1 is expressed by malignant cells in lymphoepithelial lesions.
Significance of IRTA1 in the Diagnosis of Marginal Zone Lymphoma (MZL)
In the past, MZL diagnosis relied primarily on cytological analysis and growth patterns of the tumor.
With the discovery of selective IRTA1 expression in marginal zone cells of both normal and neoplastic tissues, a more precise diagnosis of MZL is now possible using a commercially available antibody.
The anti-IRTA1 antibody (clone QM005) is specifically designed for detecting MZL in lymph nodes and extranodal sites.
Comparison of IRTA1 with Other Lymphoma Markers
✔ Immunohistochemical studies have demonstrated that IRTA1 is expressed in:
      
  • MALT lymphoma (mucosa-associated lymphoid tissue lymphoma)
    •   
  • Precursor B-cell and T-cell leukemias/lymphomas
    ✔ IRTA1 is negative in:
    •   
  • Other mature B-cell and T-cell lymphomas
    •   
  • Hodgkin lymphoma
These findings confirm that the anti-IRTA1 antibody can effectively differentiate MALT lymphoma from other low-grade B-cell lymphomas.
Validated Performance of IRTA1 Antibody (Clone QM005)
The IRTA1 antibody (clone QM005) was compared to the reference anti-IRTA1 antibody (clone MUM2) in a large cohort of nodal and extranodal MZL biopsies, as well as non-MZL lymphomas.
🔹 Both antibodies showed identical reactivity, confirming that QM005 is as specific for IRTA1 detection as the reference clone MUM2.
Summary
✔ IRTA1 is a key diagnostic marker for marginal zone lymphoma (MZL), particularly MALT lymphoma.
✔ The new anti-IRTA1 antibody (QM005) enables precise MZL diagnosis and differentiation from other low-grade B-cell lymphomas.
✔ IRTA1 is not expressed in other mature B- and T-cell lymphomas or Hodgkin lymphoma, making it a valuable tool in hematopathological diagnostics.

    • [1] Ikeda JI et al. (2017). Hum Pathol. 59:70-9.

      [2] Falini B et al. (2012). Histopathology. 61(5):930-41.

      [3] Wang Z & Cook (2019). Am J Clin Pathol. 151(3):337-43.

    • ADVANTAGES OF RECOMBINANT RABBIT MONOCLONAL ANTIBODIES

      Recombinant rabbit monoclonal antibodies—referred to as Q-clones—combine the best properties of both murine monoclonal and rabbit polyclonal antibodies, offering a broader diagnostic potential.

      Key Advantages of Our Next-Generation Recombinant Rabbit Monoclonal Antibodies

      ✔ High Affinity due to rabbit origin, enabling greater sensitivity in assays—these antibodies bind strongly to antigens and maintain their bond even under challenging conditions, unlike low-affinity antibodies.

      ✔ Superior Specificity with reduced risk of cross-reactivity, thanks to their monoclonal nature.

      ✔ Expanded Antigen Recognition—better recognition of diverse antigens and epitopes.

      ✔ Target Epitopes Poorly Recognized by Mouse-Derived Antibodies, improving detection in certain applications.

      ✔ Enhanced Response to Small-Sized Epitopes, making them ideal for challenging targets.

      ✔ Significantly Improved Recognition of Murine Antigens, broadening their usability in research and diagnostics.

      ✔ Lower Background Staining, ensuring cleaner and more reliable results.

      Recombinant vs. Hybridoma Antibody Generation

      ✔ Exceptional Consistency, Specificity, and Sensitivity—eliminating risks of gene loss, mutations, or cell line drift.

      ✔ Reliable and Controlled Production—generated from a unique gene set, ensuring stable antibody performance.

      ✔ Batch-to-Batch Consistency, guaranteeing reproducible results and long-term product availability.

      ✔ Efficient In Vitro High-Throughput Production, allowing easy standardization and scalable antibody expression for any application.

      Recombinant rabbit monoclonal antibodies represent the future of immunohistochemistry, offering unmatched reliability and precision in diagnostic and research settings.

    bottom of page